{"id":"camrelizumab-combined-gp-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Chemotherapy-related myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297715","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and reversing immune exhaustion. When combined with gemcitabine-cisplatin (GP) chemotherapy, the immunotherapy synergizes with chemotherapy-induced tumor cell death and antigen release to amplify anti-tumor immunity.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with gemcitabine and cisplatin chemotherapy for enhanced cytotoxic effect.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:44.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy)"},{"name":"Esophageal squamous cell carcinoma (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT05772208","phase":"PHASE3","title":"Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":459},{"nctId":"NCT05742750","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Camrelizumab, cisplatin and gemcitabine"],"phase":"phase_3","status":"active","brandName":"Camrelizumab combined GP chemotherapy","genericName":"Camrelizumab combined GP chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with gemcitabine and cisplatin chemotherapy for enhanced cytotoxic effect. Used for Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy), Esophageal squamous cell carcinoma (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}